臨床研究等提出・公開システム

An open-label, randomized controlled study evaluating the effectiveness of Pramipexole extended-release tablets for tardive dystonia patients

An open-label, randomized controlled study evaluating the effectiveness of Pramipexole extended-release tablets for tardive dystonia patients

Iyo Masaomi

Chiba University Hospital

1-8-1 Inohana, Chuo-ku, Chiba City, Chiba,Japan

iyom@faculty.chiba-u.jp

Kanahara Nobuhisa

Chiba University Center for Forensic Mental Health

1-8-1 Inohana, Chuo-ku, Chiba City, Chiba,Japan

+81-43-222-7171

kanahara@faculty.chiba-u.jp

Recruiting

May. 21, 2014

Interventional

randomized controlled trial

single blind

active control

parallel assignment

treatment purpose

The patient's dystonia has been confirmed to have been caused by any agent with a blocking effect of dopamine receptor (i.e., tardive dystonia) :the dystonia was not observed before the patient took the offending drug, and it emerged following medication with the drug for at least one month.
(2) Medication with an anticholinergic agent (such as biperiden, trihexyphenidyl) at a sufficient dose has been provided at least once, but was not effective for the tardive dystonia. In addition, at the time that the patient's consent to participate in the study was obtained, the Global Assessment of Functioning score of the patient did not reach 60 points due to his/her dystonia and the symptoms caused the patient profound distress.
(3) Within the 4 weeks before the patient's consent was obtained, the type and dosage of any psychotropic drugs used were not changed. Occasional use of such drugs is accepted.
(4) The patient's age at the time of consent is between 20 and 60 years old.
(5) The patient understands all aspect of the study and gives written consent. If he/she is not able to understand the study due to his/her psychiatric disease, his/her representative gives written consent.

(1) With blepharospasm or oculogyric crisis alone as a symptom of tardive dystonia
(2) Without a treatment history with anticholinergic agent
(3) Under treatment with clozapine
(4) With treatment history of deep brain stimulation (DBS)
(5) With treatment history of electroconvulsive therapy (ECT) within 3 months prior to the study enrollment
(6) With treatment history of botulinum toxin within 3 months prior to the study enrollment
(7) Participation history of a clinical trial with any intervention (i.e., except for observational study), within the most recent 3 months prior to the study enrollment
(8) Without notification of a diagnosis of psychiatric disease
(9) Pregnant or childbearing-potential women, and women who are breast-feeding
(10) With renal dysfunction: serum creatinine> 2.0 mg/dL
(11) With hypersensitivity to any ingredient of the trial drug
(12) With a suicide history within the most recent 1 year prior to the study enrolment
(13) Assessed as unsuitable for participation in the study by the study physician

Both

Tardive dystonia

Randomization of the study drug

Drug-induced extrapyramidal syndrome

G240

Burke-Fahn-Marsden scale at 16th week

Burke-Fahn-Marsden scale at 4th week
Extrapyramidal Symptom Rating Scale (ESRS)
EuroQOL(EQ-5D)Japanese version
Brief Psychiatric Rating Scale (BPRS)

+81-43-226-2616

Feb. 27, 2019

No

none